International Strategies for Tropical Disease Treatments - Experiences with Praziquantel - EDM Research Series No. 026
(1998; 113 pages) Ver el documento en el formato PDF
Índice de contenido
Ver el documentoAbstract
Ver el documentoAcknowledgments
Ver el documentoInformation on authors
Ver el documentoExchange rates used in the report
Abrir esta carpeta y ver su contenidoChapter 1: Policies for praziquantel*
Abrir esta carpeta y ver su contenidoChapter 2: Bayer & E. Merck: Discovery and development of praziquantel*
Abrir esta carpeta y ver su contenidoChapter 3: Shin Poong Pharmaceutical Co.: Process development in the Republic of Korea*
Abrir esta carpeta y ver su contenidoChapter 4: The Egyptian International Pharmaceutical Industries Co.: Praziquantel formulation*
Abrir esta carpeta y ver su contenidoChapter 5: The international supply of praziquantel*
Abrir esta carpeta y ver su contenidoChapter 6: Demand for praziquantel and national distribution*
Abrir esta carpeta y ver su contenidoChapter 7: Prices and production costs of praziquantel*
Ver el documentoOther documents in the DAP Research Series
Ver el documentoDAP Research Series No. 26
 

Other documents in the DAP Research Series

N°. 1

Injection practices research

N°. 2

How to investigate drug use in communities (also available in French)

N°. 3

Operational research on the rational use of drugs

N°. 4

Development of indicators for monitoring national drug policies

N°. 5

People's perception and use of drugs in Zimbabwe

N°. 6

Operational research in the Action Programme on Essential Drugs: Report of an informal consultation

N°. 7

How to investigate drug use in health facilities: Selected drug use indicators (also available in French and Spanish)

N°. 8

Stability of injectable oxytocics in tropical climates: Results of field surveys and simulation studies on ergometrine, methylergometrine and oxytocin

N°. 9

Prescription des antibiotiques dans trois pays d'Afrique de l'Ouest: Mauritanie, Niger et Sénégal

N°. 10

Self-medication and its impacts on essential drugs schemes in Nepal

N°. 11

Injection practices: A case study in Thailand

N°. 12

Stability of oral oxytocics in tropical climates

N°. 13

Stability of essential drugs in tropical climates: Zimbabwe

N°. 14

Injection practices: A case study of Uganda

N°. 15

Community health workers and drugs: A case study of Thailand

N°. 16

Use of the WHO Certification Scheme on the Quality of Pharmaceutical Products Moving in International Commerce

N°. 17

Impact of a short course in pharmacotherapy for undergraduate medical students: An international multicentre study

N°. 18

La qualité des médicaments sur le marché pharmaceutique africain. Etude analytique dans trois pays: Cameroun, Madagascar, Tchad

N°. 19

Operational research projects in the Action Programme on Essential Drugs: An annotated inventory

N°. 20

Injection practices in the developing world. A comparative review of field studies in Uganda and Indonesia

N°. 21

Le secteur pharmaceutique privé commercial au Maroc: Dynamique de développement et effets sur l’accessibilité des médicaments

N°. 22

La libéralisation du secteur pharmaceutique en Algérie: Effets sur la disponibilité et les prix des médicaments

N°. 23

Le secteur pharmaceutique privé commercial au Sénégal: Dynamique de développement et effets sur l’accès aux médicaments essentiels

N°. 24

Public education in rational drug use: A global survey

N°. 25

Comparative analysis of national drug policies - Second workshop, Geneva, 10-13 June 1996

 

Ir a la sección anterior Ir a la siguiente sección
 

Última actualización: le 3 mayo 2013